Compare FTLF & MBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTLF | MBOT |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.0M | 114.9M |
| IPO Year | 2006 | 2000 |
| Metric | FTLF | MBOT |
|---|---|---|
| Price | $11.50 | $1.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $21.50 | $7.50 |
| AVG Volume (30 Days) | 41.2K | ★ 782.4K |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.27 |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $21,744,000.00 | $116,887.00 |
| Revenue This Year | $45.76 | N/A |
| Revenue Next Year | $5.10 | $119.77 |
| P/E Ratio | $67.65 | ★ N/A |
| Revenue Growth | ★ 11.52 | N/A |
| 52 Week Low | $8.67 | $1.60 |
| 52 Week High | $20.98 | $4.62 |
| Indicator | FTLF | MBOT |
|---|---|---|
| Relative Strength Index (RSI) | 56.81 | 52.06 |
| Support Level | $9.11 | $1.65 |
| Resistance Level | $12.55 | $2.21 |
| Average True Range (ATR) | 0.88 | 0.08 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 51.98 | 54.62 |
FitLife Brands Inc is a provider of proprietary nutritional supplements for health-conscious consumers. The company markets and sells its products under NDS, PMD, Siren labs, Core active, Metis nutrition, Dr. Tobias, MusclePharm, Irwin Naturals, Applied Nutrition, Isatori, and Nature's Secret brand names. Its product portfolio consists of sports nutrition, energy, sports drink products, meal replacement products, and weight loss products. The firm derives its revenue from product sales. Its product categories include Natural & Organic Foods, Functional Foods, Natural & Organic Personal Care and Household Products, and Supplements.
Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.